Efecto Antifúngico de un Péptido Antimicrobiano Extraído de Atta laevigata en Especies de Candida spp

Autor: Gonzalez-Correa, Karen Viviana, Mier-Cadena, Jhorman Jair, Santos-García, Natalia

Digital
Introducción: El impacto que ha generado la resistencia de Candida spp. a los diferentes antifúngicos con los que era tratadas sus infecciones en el sector de la salud es cada vez más grande, es por esto por lo que en la actualidad se

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______7085::c95cf3e5a00a67a0256d8b35d3873d09
https://repositorio.udes.edu.co/handle/001/6569

Atividade biológica de Cryptococcus neoformans e Cryptococcus gattii provenientes de isolados clínicos e ambientais

Autor: Maria Aparecida de Resende Stoianoff, Rita de Cássia Trindade, Antônio Márcio Barbosa Júnior, Dângelly Lins Figuerôa Martins de Mélo, Bruno Fernandes de Oliveira Santos, Erick de Oliveira Carvalho

Publikováno v: Jornal Brasileiro de Patologia e Medicina Laboratorial, Vol 49, Iss 3, Pp 160-168 (2013)
Jornal Brasileiro de Patologia e Medicina Laboratorial v.49 n.3 2013
Jornal Brasileiro de Patologia e Medicina Laboratorial
Sociedade Brasileira de Patologia (SBP)
instacron:SBP
Repositório Institucional da UFS
Universidade Federal de Sergipe (UFS)
instacron:UFS
Jornal Brasileiro de Patologia e Medicina Laboratorial, Volume: 49, Issue: 3, Pages: 160-168, Published: JUN 2013

INTRODUCTION: Cryptococcus neoformans and Cryptococcus gattii are encapsulated basidiomycetous yeasts with worldwide distribution. They cause cryptococcosis with features of systemic infection, affecting the central nervous system, lungs and skin in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d92f0520b3148725c4ca9affd4970abf
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1676-24442013000300002&lng=en&tlng=en

The role of the FKS1 gene in nosocomial Candida albicans isolates’ virulence and antifungal resistance

Autor: Giovanni Rodriguez-Leguizamon

Publikováno v: Giovanni Rodriguez-Leguizamon
Whittington A: From commensal to pathogen: Candida albicans. In: Human Fungal Pathogens. Edited by Kurzai O. Berlin Heidelberg: Springer-Verlag; 2014: 3-18.
Pfaller MA, Diekema DJ: Epidemiology of invasive mycoses in North America. Critical reviews in microbiology 2010 36(1):1-53
Pfaller MA: Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin Infect Dis 1996, 22 Suppl 2:S89-94
Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB: Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004, 39(3):309-317
Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, Messer S, Herwaldt L, Pfaller M, Diekema D: Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003, 37(9):1172-1177
Pfaller MA, Diekema DJ: Epidemiology of invasive candidiasis: a persistent public health problem. Clinical microbiology reviews 2007, 20(1):133-163
DiazGranados CA, Martinez A, Deaza C, Valderrama S: An outbreak of Candida spp. bloodstream infection in a tertiary care center in Bogota, Colombia. Braz J Infect Dis 2008, 12(5):390-394
Sullivan DJ, Moran GP, Pinjon E, Al-Mosaid A, Stokes C, Vaughan C, Coleman DC: Comparison of the epidemiology, drug resistance mechanisms, and virulence of Candida dubliniensis and Candida albicans. FEMS yeast research 2004, 4(4-5):369-376
Pfaller MA, Diekema DJ, Rinaldi MG, Barnes R, Hu B, Veselov AV, Tiraboschi N, Nagy E, Gibbs DL: Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. Journal of clinical microbiology 2005, 43(12):5848-5859
Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Diekema DJ: In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. Journal of clinical microbiology 2008, 46(1):150-156
Walker LA, Gow NA, Munro CA: Fungal echinocandin resistance. Fungal Genet Biol 2010, 47(2):117-126
Dannaoui E, Desnos-Ollivier M, Garcia-Hermoso D, Grenouillet F, Cassaing S, Baixench MT, Bretagne S, Dromer F, Lortholary O, French Mycoses Study G: Candida spp. with acquired echinocandin resistance, France, 2004-2010. Emerging infectious diseases 2012, 18(1):86-90
Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr., Calandra TF, Edwards JE, Jr., Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L et al: Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48(5):503-535
Shapiro RS, Robbins N, Cowen LE: Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol Mol Biol Rev 2011, 75(2):213-267
Park S, Kelly R, Kahn JN, Robles J, Hsu MJ, Register E, Li W, Vyas V, Fan H, Abruzzo G et al: Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrobial agents and chemotherapy 2005, 49(8):3264-3273
Sorgo AG, Heilmann CJ, Dekker HL, Bekker M, Brul S, de Koster CG, de Koning LJ, Klis FM: Effects of fluconazole on the secretome, the wall proteome, and wall integrity of the clinical fungus Candida albicans. Eukaryotic cell 2011, 10(8):1071-1081
Brandt ME: Recent taxonomic developments with Candida and other opportunistic yeasts. Curr Fungal Infect Rep 2012, 6(3):170-177
Hedges SB: The origin and evolution of model organisms. Nature reviews Genetics 2002, 3(11):838-849
Criseo G, Scordino F, Romeo O: Current methods for identifying clinically important cryptic Candida species. Journal of microbiological methods 2015, 111C:50-56
Ngouana TK, Krasteva D, Drakulovski P, Toghueo RK, Kouanfack C, Ambe A, Reynes J, Delaporte E, Boyom FF, Mallie M et al: Investigation of minor species Candida africana, Candida stellatoidea and Candida dubliniensis in the Candida albicans complex among Yaounde (Cameroon) HIV-infected patients. Mycoses 2015, 58(1):33-39
Tietz HJ, Hopp M, Schmalreck A, Sterry W, Czaika V: Candida africana sp. nov., a new human pathogen or a variant of Candida albicans? Mycoses 2001, 44(11-12):437-445.
Berman J, Sudbery PE: Candida Albicans: a molecular revolution built on lessons from budding yeast. Nature reviews Genetics 2002, 3(12):918-930
Sudbery PE: Growth of Candida albicans hyphae. Nature reviews 2011, 9(10):737-748
Wahab AA, Taj-Aldeen SJ, Kolecka A, ElGindi M, Finkel JS, Boekhout T: High prevalence of Candida dubliniensis in lower respiratory tract secretions from cystic fibrosis patients may be related to increased adherence properties. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2014, 24:14-19
Sullivan DJ, Westerneng TJ, Haynes KA, Bennett DE, Coleman DC: Candida dubliniensis sp. nov.: phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. Microbiology 1995, 141 ( Pt 7):1507-1521
Jones T, Federspiel NA, Chibana H, Dungan J, Kalman S, Magee BB, Newport G, Thorstenson YR, Agabian N, Magee PT et al: The diploid genome sequence of Candida albicans. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(19):7329-7334
Butler G, Rasmussen MD, Lin MF, Santos MA, Sakthikumar S, Munro CA, Rheinbay E, Grabherr M, Forche A, Reedy JL et al: Evolution of pathogenicity and sexual reproduction in eight Candida genomes. Nature 2009, 459(7247):657-662
De Backer MD, Magee PT, Pla J: Recent developments in molecular genetics of Candida albicans. Annual review of microbiology 2000, 54:463-498
Santos MA, Tuite MF: The CUG codon is decoded in vivo as serine and not leucine in Candida albicans. Nucleic acids research 1995, 23(9):1481-1486
Arnaud MB, Inglis DO, Skrzypek MS, Binkley J, Shah P, Wymore F, Binkley G, Miyasato SR, Simison M, Sherlock G: Candida Genome Database. http://www.candidagenome.org/ (Last accessed may 19th 2015)
Forche A, Alby K, Schaefer D, Johnson AD, Berman J, Bennett RJ: The parasexual cycle in Candida albicans provides an alternative pathway to meiosis for the formation of recombinant strains. PLoS biology 2008, 6(5):e110
Ruiz-Herrera J, Elorza MV, Valentin E, Sentandreu R: Molecular organization of the cell wall of Candida albicans and its relation to pathogenicity. FEMS yeast research 2006, 6(1):14-29
Brown JA, Catley BJ: Monitoring polysaccharide synthesis in Candida albicans. Carbohydrate Research 1992, 227:195-202
Gow NA, van de Veerdonk FL, Brown AJ, Netea MG: Candida albicans morphogenesis and host defence: discriminating invasion from colonization. Nature reviews 2012, 10(2):112-122
Chaffin WL: Candida albicans cell wall proteins. Microbiol Mol Biol Rev 2008, 72(3):495-544
Plaine A, Walker L, Da Costa G, Mora-Montes HM, McKinnon A, Gow NA, Gaillardin C, Munro CA, Richard ML: Functional analysis of Candida albicans GPI-anchored proteins: roles in cell wall integrity and caspofungin sensitivity. Fungal Genet Biol 2008, 45(10):1404-1414
Bruno VM, Kalachikov S, Subaran R, Nobile CJ, Kyratsous C, Mitchell AP: Control of the C. albicans cell wall damage response by transcriptional regulator Cas5. PLoS pathogens 2006, 2(3):e21
Liu TT, Lee RE, Barker KS, Lee RE, Wei L, Homayouni R, Rogers PD: Genome-wide expression profiling of the response to azole, polyene, echinocandin, and pyrimidine antifungal agents in Candida albicans. Antimicrobial agents and chemotherapy 2005, 49(6):2226-2236
Barchiesi F, Orsetti E, Gesuita R, Skrami E, Manso E, Candidemia Study G: Epidemiology, clinical characteristics, and outcome of candidemia in a tertiary referral center in Italy from 2010 to 2014. Infection 2015
Diekema D, Arbefeville S, Boyken L, Kroeger J, Pfaller M: The changing epidemiology of healthcare-associated candidemia over three decades. Diagnostic microbiology and infectious disease 2012, 73(1):45-48
Nucci M, Queiroz-Telles F, Tobon AM, Restrepo A, Colombo AL: Epidemiology of opportunistic fungal infections in Latin America. Clin Infect Dis 2010, 51(5):561-570
Chen PY, Chuang YC, Wang JT, Sheng WH, Yu CJ, Chu CC, Hsueh PR, Chang SC, Chen YC: Comparison of epidemiology and treatment outcome of patients with candidemia at a teaching hospital in Northern Taiwan, in 2002 and 2010. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi 2014, 47(2):95-103
Wilson LS, Reyes CM, Stolpman M, Speckman J, Allen K, Beney J: The direct cost and incidence of systemic fungal infections. Value Health 2002, 5(1):26-34
Blot SI, Depuydt P, Annemans L, Benoit D, Hoste E, De Waele JJ, Decruyenaere J, Vogelaers D, Colardyn F, Vandewoude KH: Clinical and economic outcomes in critically ill patients with nosocomial catheter-related bloodstream infections. Clin Infect Dis 2005, 41(11):1591-1598
Moran C, Grussemeyer CA, Spalding JR, Benjamin DK, Jr., Reed SD: Comparison of costs, length of stay, and mortality associated with Candida glabrata and Candida albicans bloodstream infections. American journal of infection control 2010, 38(1):78-80
Calderone RA: Candida and candidiasis, 2nd edn. Washington D.C., U.S.A.; 2012
Kadosh D, Johnson AD: Induction of the Candida albicans filamentous growth program by relief of transcriptional repression: a genome-wide analysis. Molecular biology of the cell 2005, 16(6):2903-2912
Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J: Harrison's principles of internal medicine, 18th edn: McGraw-Hill; 2012
Hermsen ED, Zapapas MK, Maiefski M, Rupp ME, Freifeld AG, Kalil AC: Validation and comparison of clinical prediction rules for invasive candidiasis in intensive care unit patients: a matched case-control study. Critical care (London, England) 2011, 15(4):R198
Garner JS: Infection control and applied epidemiology. St. Louis, MI, U.S.A.: Mosby; 1996
Horan TC, Andrus M, Dudeck MA: CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. American journal of infection control 2008, 36(5):309-332
Perlroth J, Choi B, Spellberg B: Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med Mycol 2007, 45(4):321-346
Sydnor ER, Perl TM: Hospital epidemiology and infection control in acute-care settings. Clinical microbiology reviews 2011, 24(1):141-173
Ostrosky-Zeichner L, Casadevall A, Galgiani JN, Odds FC, Rex JH: An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov 2010, 9(9):719-727
Maubon D, Garnaud C, Calandra T, Sanglard D, Cornet M: Resistance of Candida spp. to antifungal drugs in the ICU: where are we now? Intensive care medicine 2014, 40(9):1241-1255
Anderson TM, Clay MC, Cioffi AG, Diaz KA, Hisao GS, Tuttle MD, Nieuwkoop AJ, Comellas G, Maryum N, Wang S et al: Amphotericin forms an extramembranous and fungicidal sterol sponge. Nature chemical biology 2014, 10(5):400-406
Hope WW, Tabernero L, Denning DW, Anderson MJ: Molecular mechanisms of primary resistance to flucytosine in Candida albicans. Antimicrobial agents and chemotherapy 2004, 48(11):4377-4386
Eschenauer G, Depestel DD, Carver PL: Comparison of echinocandin antifungals. Therapeutics and clinical risk management 2007, 3(1):71-97
Perlin DS: Resistance to echinocandin-class antifungal drugs. Drug Resist Updat 2007, 10(3):121-130
Denning DW: Echinocandin antifungal drugs. Lancet 2003, 362(9390):1142-1151
Deresinski SC, Stevens DA: Caspofungin. Clin Infect Dis 2003, 36(11):1445-1457
Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S et al: ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012, 18 Suppl 7:19-37
Ullmann AJ, Akova M, Herbrecht R, Viscoli C, Arendrup MC, Arikan-Akdagli S, Bassetti M, Bille J, Calandra T, Castagnola E et al: ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect 2012, 18 Suppl 7:53-67
Cowen LE: The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype. Nature reviews 2008, 6(3):187-198
Rogers TR: Antifungal drug resistance: limited data, dramatic impact? International journal of antimicrobial agents 2006, 27 Suppl 1:7-11
Sanglard D, Coste A, Ferrari S: Antifungal drug resistance mechanisms in fungal pathogens from the perspective of transcriptional gene regulation. FEMS yeast research 2009, 9(7):1029-1050
Schuetzer-Muehlbauer M, Willinger B, Krapf G, Enzinger S, Presterl E, Kuchler K: The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin. Molecular microbiology 2003, 48(1):225-235
Watamoto T, Samaranayake LP, Egusa H, Yatani H, Seneviratne CJ: Transcriptional regulation of drug-resistance genes in Candida albicans biofilms in response to antifungals. Journal of medical microbiology 2011, 60(Pt 9):1241-1247
Perlin DS: Current perspectives on echinocandin class drugs. Future microbiology 2011, 6(4):441-457
Ramage G, Saville SP, Thomas DP, Lopez-Ribot JL: Candida biofilms: an update. Eukaryotic cell 2005, 4(4):633-638
Ramage G, Martinez JP, Lopez-Ribot JL: Candida biofilms on implanted biomaterials: a clinically significant problem. FEMS yeast research 2006, 6(7):979-986
Singh SD, Robbins N, Zaas AK, Schell WA, Perfect JR, Cowen LE: Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. PLoS pathogens 2009, 5(7):e1000532
Ramage G, Rajendran R, Sherry L, Williams C: Fungal biofilm resistance. International journal of microbiology 2012, 2012:528521
Laverdiere M, Lalonde RG, Baril JG, Sheppard DC, Park S, Perlin DS: Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. The Journal of antimicrobial chemotherapy 2006, 57(4):705-708
Garcia-Effron G, Park S, Perlin DS: Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrobial agents and chemotherapy 2009, 53(1):112-122
Balashov SV, Park S, Perlin DS: Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrobial agents and chemotherapy 2006, 50(6):2058-2063
Miller CD, Lomaestro BW, Park S, Perlin DS: Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacotherapy 2006, 26(6):877-880
Katiyar S, Pfaller M, Edlind T: Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrobial agents and chemotherapy 2006, 50(8):2892-2894
Baixench MT, Aoun N, Desnos-Ollivier M, Garcia-Hermoso D, Bretagne S, Ramires S, Piketty C, Dannaoui E: Acquired resistance to echinocandins in Candida albicans: case report and review. The Journal of antimicrobial chemotherapy 2007, 59(6):1076-1083
Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart SR, Motyl M, Perlin DS: Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist Updat 2011, 14(3):164-176
Wiederhold NP, Grabinski JL, Garcia-Effron G, Perlin DS, Lee SA: Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans. Antimicrobial agents and chemotherapy 2008, 52(11):4145-4148
Poulain D, Jouault T: Candida albicans cell wall glycans, host receptors and responses: elements for a decisive crosstalk. Current opinion in microbiology 2004, 7(4):342-349
Nather K, Munro CA: Generating cell surface diversity in Candida albicans and other fungal pathogens. FEMS microbiology letters 2008, 285(2):137-145
Cowen LE, Steinbach WJ: Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryotic cell 2008, 7(5):747-764
Angiolella L, Stringaro AR, De Bernardis F, Posteraro B, Bonito M, Toccacieli L, Torosantucci A, Colone M, Sanguinetti M, Cassone A et al: Increase of virulence and its phenotypic traits in drug-resistant strains of Candida albicans. Antimicrobial agents and chemotherapy 2008, 52(3):927-936
Wiederhold NP, Kontoyiannis DP, Prince RA, Lewis RE: Attenuation of the activity of caspofungin at high concentrations against candida albicans: possible role of cell wall integrity and calcineurin pathways. Antimicrobial agents and chemotherapy 2005, 49(12):5146-5148
Rauceo JM, Blankenship JR, Fanning S, Hamaker JJ, Deneault JS, Smith FJ, Nantel A, Mitchell AP: Regulation of the Candida albicans cell wall damage response by transcription factor Sko1 and PAS kinase Psk1. Molecular biology of the cell 2008, 19(7):2741-2751
Onyewu C, Wormley FL, Jr., Perfect JR, Heitman J: The calcineurin target, Crz1, functions in azole tolerance but is not required for virulence of Candida albicans. Infection and immunity 2004, 72(12):7330-7333
Perlin DS: Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management. Drugs 2014, 74(14):1573-1585
Shields RK, Nguyen MH, Du C, Press E, Cheng S, Clancy CJ: Paradoxical effect of caspofungin against Candida bloodstream isolates is mediated by multiple pathways but eliminated in human serum. Antimicrobial agents and chemotherapy 2011, 55(6):2641-2647
Stevens DA, Ichinomiya M, Koshi Y, Horiuchi H: Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin. Antimicrobial agents and chemotherapy 2006, 50(9):3160-3161
Gauwerky K, Borelli C, Korting HC: Targeting virulence: a new paradigm for antifungals. Drug discovery today 2009, 14(3-4):214-222
Wilson D, Thewes S, Zakikhany K, Fradin C, Albrecht A, Almeida R, Brunke S, Grosse K, Martin R, Mayer F et al: Identifying infection-associated genes of Candida albicans in the postgenomic era. FEMS yeast research 2009, 9(5):688-700
Nailis H, Kucharikova S, Ricicova M, Van Dijck P, Deforce D, Nelis H, Coenye T: Real-time PCR expression profiling of genes encoding potential virulence factors in Candida albicans biofilms: identification of model-dependent and-independent gene expression. BMC microbiology 2010, 10:114
Felk A, Kretschmar M, Albrecht A, Schaller M, Beinhauer S, Nichterlein T, Sanglard D, Korting HC, Schafer W, Hube B: Candida albicans hyphal formation and the expression of the Efg1-regulated proteinases Sap4 to Sap6 are required for the invasion of parenchymal organs. Infection and immunity 2002, 70(7):3689-3700
Wayne PA: CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeast; CLSI document M27-A3; 2008
Rodriguez-Tudela JL: EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect 2008, 14(4):398-405
Espinel-Ingroff A, Arendrup MC, Pfaller MA, Bonfietti LX, Bustamante B, Canton E, Chryssanthou E, Cuenca-Estrella M, Dannaoui E, Fothergill A et al: Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent? Antimicrobial agents and chemotherapy 2013, 57(12):5836-5842
Wayne PA: CLSI. Reference Method for Broth Dilution Antifungal Suscetibility Testing of Yeasts; Fourth Informational Supplement. CLSI Document M27-S4; 2012
Pfaller MA, Diekema DJ, Ostrosky-Zeichner L, Rex JH, Alexander BD, Andes D, Brown SD, Chaturvedi V, Ghannoum MA, Knapp CC et al: Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. Journal of clinical microbiology 2008, 46(8):2620-2629
Espinel-Ingroff A: In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 2003, 20(4):121-136
Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, Powderly WG, Hyslop N, Kauffman CA, Cleary J et al: Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrobial agents and chemotherapy 2003, 47(10):3149-3154
Espinel-Ingroff A, Canton E, Peman J, Martin-Mazuelo E: Comparison of anidulafungin MICs determined by the clinical and laboratory standards institute broth microdilution method (M27-A3 document) and Etest for Candida species isolates. Antimicrobial agents and chemotherapy 2010, 54(3):1347-1350
Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Moet GJ, Jones RN: Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species. Journal of clinical microbiology 2010, 48(5):1592-1599
Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Jones RN, Turnidge J, Diekema DJ: Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. Journal of clinical microbiology 2010, 48(1):52-56
Arendrup MC, Cuenca-Estrella M, Lass-Florl C, Hope WW: Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. Drug Resist Updat 2013, 16(6):81-95
Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ: Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods. Journal of clinical microbiology 2006, 44(10):3533-3538
Arendrup MC, Garcia-Effron G, Lass-Florl C, Lopez AG, Rodriguez-Tudela JL, Cuenca-Estrella M, Perlin DS: Echinocandin susceptibility testing of Candida species: comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media. Antimicrobial agents and chemotherapy 2010, 54(1):426-439
Ministerio de Protección Social: Resolución 8430. In. Bogotá, Colombia; 1993
WMA Declaration of Helsinki: Ethical Principles for Human Research Involving Human Subjects. In. Seoul, Korea; 2008
Garner J.S: Infection Control and Applied Epidemiology. St. Louis: Mosby; 1996.
Pfaller MA, Bale M, Buschelman B, Lancaster M, Espinel-Ingroff A, Rex JH, Rinaldi MG: Selection of candidate quality control isolates and tentative quality control ranges for in vitro susceptibility testing of yeast isolates by National Committee for Clinical Laboratory Standards proposed standard methods. Journal of clinical microbiology 1994, 32(7):1650-1653
Koszul R, Malpertuy A, Frangeul L, Bouchier C, Wincker P, Thierry A, Duthoy S, Ferris S, Hennequin C, Dujon B: The complete mitochondrial genome sequence of the pathogenic yeast Candida (Torulopsis) glabrata. FEBS letters 2003, 534(1-3):39-48
Ramage G, Vandewalle K, Wickes BL, Lopez-Ribot JL: Characteristics of biofilm formation by Candida albicans. Rev Iberoam Micol 2001, 18(4):163-170
Maidan MM, De Rop L, Relloso M, Diez-Orejas R, Thevelein JM, Van Dijck P: Combined inactivation of the Candida albicans GPR1 and TPS2 genes results in avirulence in a mouse model for systemic infection. Infection and immunity 2008, 76(4):1686-1694
Wilson D, Fiori A, Brucker KD, Dijck PV, Stateva L: Candida albicans Pde1p and Gpa2p comprise a regulatory module mediating agonist-induced cAMP signalling and environmental adaptation. Fungal Genet Biol 2010, 47(9):742-752
Cuetara MS, Alhambra A, Del Palacio A: [Traditional microbiological diagnosis for invasive candidiasis in critical non-neutropenic patients]. Rev Iberoam Micol 2006, 23(1):4-7
Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25(4):402-408
Walker LA, Gow NA, Munro CA: Elevated chitin content reduces the susceptibility of Candida species to caspofungin. Antimicrobial agents and chemotherapy 2013, 57(1):146-154
Cendejas-Bueno E, Kolecka A, Alastruey-Izquierdo A, Theelen B, Groenewald M, Kostrzewa M, Cuenca-Estrella M, Gomez-Lopez A, Boekhout T: Reclassification of the Candida haemulonii complex as Candida haemulonii (C. haemulonii group I), C. duobushaemulonii sp. nov. (C. haemulonii group II), and C. haemulonii var. vulnera var. nov.: three multiresistant human pathogenic yeasts. Journal of clinical microbiology 2012, 50(11):3641-3651
Qian J, Cutler JE, Cole RB, Cai Y: MALDI-TOF mass signatures for differentiation of yeast species, strain grouping and monitoring of morphogenesis markers. Analytical and bioanalytical chemistry 2008, 392(3):439-449
Suzuki R, Shimodaira H: Pvclust: an R package for assessing the uncertainty in hierarchical clustering. Bioinformatics 2006, 22(12):1540-1542
Alberti-Segui C, Morales AJ, Xing H, Kessler MM, Willins DA, Weinstock KG, Cottarel G, Fechtel K, Rogers B: Identification of potential cell-surface proteins in Candida albicans and investigation of the role of a putative cell-surface glycosidase in adhesion and virulence. Yeast (Chichester, England) 2004, 21(4):285-302
White TJ BT, Lee S, Taylor J.: Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics. In: PCR Protocols: A Guide Methods and Applications. Edited by Innis A GD, Snisky JJ, White TJ. San Diego, CA: Academic Press; 1990: 315-322
Romeo O, Criseo G: First molecular method for discriminating between Candida africana, Candida albicans, and Candida dubliniensis by using hwp1 gene. Diagnostic microbiology and infectious disease 2008, 62(2):230-233
Edwards JE, Jr., Bodey GP, Bowden RA, Buchner T, de Pauw BE, Filler SG, Ghannoum MA, Glauser M, Herbrecht R, Kauffman CA et al: International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis 1997, 25(1):43-59
Eggimann P, Ostrosky-Zeichner L: Early antifungal intervention strategies in ICU patients. Current opinion in critical care 2010, 16(5):465-469
Asmundsdottir LR, Erlendsdottir H, Haraldsson G, Guo H, Xu J, Gottfredsson M: Molecular epidemiology of candidemia: evidence of clusters of smoldering nosocomial infections. Clin Infect Dis 2008, 47(2):e17-24
Drakulovski P, Dunyach C, Bertout S, Reynes J, Mallie M: A Candida albicans strain with high MIC for caspofungin and no FKS1 mutations exhibits a high chitin content and mutations in two chitinase genes. Med Mycol 2011, 49(5):467-474
Gomez J, Garcia-Vazquez E, Hernandez A, Espinosa C, Ruiz J: [Nosocomial candidemia: new challenges of an emergent problem]. Rev Esp Quimioter 2010, 23(4):158-168
Morrell M, Fraser VJ, Kollef MH: Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrobial agents and chemotherapy 2005, 49(9):3640-3645
Baillie GS, Douglas LJ: Effect of growth rate on resistance of Candida albicans biofilms to antifungal agents. Antimicrobial agents and chemotherapy 1998, 42(8):1900-1905
Ernst JF, Pla J: Signaling the glycoshield: maintenance of the Candida albicans cell wall. International journal of medical microbiology : IJMM 2011, 301(5):378-383
Brauer MJ, Huttenhower C, Airoldi EM, Rosenstein R, Matese JC, Gresham D, Boer VM, Troyanskaya OG, Botstein D: Coordination of growth rate, cell cycle, stress response, and metabolic activity in yeast. Molecular biology of the cell 2008, 19(1):352-367
Kucharikova S, Tournu H, Lagrou K, Van Dijck P, Bujdakova H: Detailed comparison of Candida albicans and Candida glabrata biofilms under different conditions and their susceptibility to caspofungin and anidulafungin. Journal of medical microbiology 2011, 60(Pt 9):1261-1269
Staab JF, Bradway SD, Fidel PL, Sundstrom P: Adhesive and mammalian transglutaminase substrate properties of Candida albicans Hwp1. Science 1999, 283(5407):1535-1538
Cowen LE, Anderson JB, Kohn LM: Evolution of drug resistance in Candida albicans. Annual review of microbiology 2002, 56:139-165
Maidan MM, Thevelein JM, Van Dijck P: Carbon source induced yeast-to-hypha transition in Candida albicans is dependent on the presence of amino acids and on the G-protein-coupled receptor Gpr1. Biochemical Society transactions 2005, 33(Pt 1):291-293
Homann OR, Dea J, Noble SM, Johnson AD: A phenotypic profile of the Candida albicans regulatory network. PLoS genetics 2009, 5(12):e1000783
Han TL, Cannon RD, Villas-Boas SG: The metabolic basis of Candida albicans morphogenesis and quorum sensing. Fungal Genet Biol 2011, 48(8):747-763
Liu H, Kohler J, Fink GR: Suppression of hyphal formation in Candida albicans by mutation of a STE12 homolog. Science 1994, 266(5191):1723-1726
Toenjes KA, Munsee SM, Ibrahim AS, Jeffrey R, Edwards JE, Jr., Johnson DI: Small-molecule inhibitors of the budded-to-hyphal-form transition in the pathogenic yeast Candida albicans. Antimicrobial agents and chemotherapy 2005, 49(3):963-972
Peeters T, Versele M, Thevelein JM: Directly from Galpha to protein kinase A: the kelch repeat protein bypass of adenylate cyclase. Trends in biochemical sciences 2007, 32(12):547-554
Kadosh D, Lopez-Ribot JL: Candida albicans: adapting to succeed. Cell host & microbe 2013, 14(5):483-485
Braun BR, Kadosh D, Johnson AD: NRG1, a repressor of filamentous growth in C.albicans, is down-regulated during filament induction. The EMBO journal 2001, 20(17):4753-4761
Nobile CJ, Fox EP, Nett JE, Sorrells TR, Mitrovich QM, Hernday AD, Tuch BB, Andes DR, Johnson AD: A recently evolved transcriptional network controls biofilm development in Candida albicans. Cell 2012, 148(1-2):126-138
Martel CM, Parker JE, Bader O, Weig M, Gross U, Warrilow AG, Kelly DE, Kelly SL: A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B. Antimicrobial agents and chemotherapy 2010, 54(9):3578-3583
Markovich S, Yekutiel A, Shalit I, Shadkchan Y, Osherov N: Genomic approach to identification of mutations affecting caspofungin susceptibility in Saccharomyces cerevisiae. Antimicrobial agents and chemotherapy 2004, 48(10):3871-3876
Barker KS, Crisp S, Wiederhold N, Lewis RE, Bareither B, Eckstein J, Barbuch R, Bard M, Rogers PD: Genome-wide expression profiling reveals genes associated with amphotericin B and fluconazole resistance in experimentally induced antifungal resistant isolates of Candida albicans. The Journal of antimicrobial chemotherapy 2004, 54(2):376-385
Zhang N, Cannon RD, Holland BR, Patchett ML, Schmid J: Impact of genetic background on allele selection in a highly mutable Candida albicans gene, PNG2. PloS one 2010, 5(3):e9614
Munro CA, Selvaggini S, de Bruijn I, Walker L, Lenardon MD, Gerssen B, Milne S, Brown AJ, Gow NA: The PKC, HOG and Ca2+ signalling pathways co-ordinately regulate chitin synthesis in Candida albicans. Molecular microbiology 2007, 63(5):1399-1413
Walker LA, Munro CA, de Bruijn I, Lenardon MD, McKinnon A, Gow NA: Stimulation of chitin synthesis rescues Candida albicans from echinocandins. PLoS pathogens 2008, 4(4):e1000040
Nishiyama Y, Uchida K, Yamaguchi H: Morphological changes of Candida albicans induced by micafungin (FK463), a water-soluble echinocandin-like lipopeptide. Journal of electron microscopy 2002, 51(4):247-255
Bader O, Weig M, Taverne-Ghadwal L, Lugert R, Gross U, Kuhns M: Improved clinical laboratory identification of human pathogenic yeasts by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clin Microbiol Infect 2011, 17(9):1359-1365
Vlek A, Kolecka A, Khayhan K, Theelen B, Groenewald M, Boel E, Boekhout T: Interlaboratory comparison of sample preparation methods, database expansions, and cutoff values for identification of yeasts by matrix-assisted laser desorption ionization-time of flight mass spectrometry using a yeast test panel. Journal of clinical microbiology 2014, 52(8):3023-3029
Tan KE, Ellis BC, Lee R, Stamper PD, Zhang SX, Carroll KC: Prospective evaluation of a matrix-assisted laser desorption ionization-time of flight mass spectrometry system in a hospital clinical microbiology laboratory for identification of bacteria and yeasts: a bench-by-bench study for assessing the impact on time to identification and cost-effectiveness. Journal of clinical microbiology 2012, 50(10):3301-3308
Alonso-Vargas R, Elorduy L, Eraso E, Cano FJ, Guarro J, Ponton J, Quindos G: Isolation of Candida africana, probable atypical strains of Candida albicans, from a patient with vaginitis. Med Mycol 2008, 46(2):167-170
Dieng Y, Sow D, Ndiaye M, Guichet E, Faye B, Tine R, Lo A, Sylla K, Ndiaye M, Abiola A et al: [Identification of three Candida africana strains in Senegal]. Journal de mycologie medicale 2012, 22(4):335-340
Nnadi NE, Ayanbimpe GM, Scordino F, Okolo MO, Enweani IB, Criseo G, Romeo O: Isolation and molecular characterization of Candida africana from Jos, Nigeria. Med Mycol 2012, 50(7):765-767
Romeo O, Criseo G: Morphological, biochemical and molecular characterisation of the first Italian Candida africana isolate. Mycoses 2009, 52(5):454-457
Odds FC, Bougnoux ME, Shaw DJ, Bain JM, Davidson AD, Diogo D, Jacobsen MD, Lecomte M, Li SY, Tavanti A et al: Molecular phylogenetics of Candida albicans. Eukaryotic cell 2007, 6(6):1041-1052
Romeo O TH, Criseo G.: Candida africana: It is a fungal pathogen? Curr Fungal Infect Rep 2013, 7:192-197
Pulcrano G, Iula DV, Vollaro A, Tucci A, Cerullo M, Esposito M, Rossano F, Catania MR: Rapid and reliable MALDI-TOF mass spectrometry identification of Candida non-albicans isolates from bloodstream infections. Journal of microbiological methods 2013, 94(3):262-266
De Carolis E, Vella A, Vaccaro L, Torelli R, Posteraro P, Ricciardi W, Sanguinetti M, Posteraro B: Development and validation of an in-house database for matrix-assisted laser desorption ionization-time of flight mass spectrometry-based yeast identification using a fast protein extraction procedure. Journal of clinical microbiology 2014, 52(5):1453-1458
Pedreno Y, Maicas S, Arguelles JC, Sentandreu R, Valentin E: The ATC1 gene encodes a cell wall-linked acid trehalase required for growth on trehalose in Candida albicans. The Journal of biological chemistry 2004, 279(39):40852-40860
Ram SP, Romana LK, Shepherd MG, Sullivan PA: Exo-(1----3)-beta-glucanase, autolysin and trehalase activities during yeast growth and germ-tube formation in Candida albicans. Journal of general microbiology 1984, 130(5):1227-1236
Peterson SW, Kurtzman CP: Ribosomal RNA sequence divergence among sibling species of yeasts. Syst Appl Microbiol 1991, 14:124-129
Borman AM, Szekely A, Linton CJ, Palmer MD, Brown P, Johnson EM: Epidemiology, antifungal susceptibility, and pathogenicity of Candida africana isolates from the United Kingdom. Journal of clinical microbiology 2013, 51(3):967-972
Shan Y, Fan S, Liu X, Li J: Prevalence of Candida albicans-closely related yeasts, Candida africana and Candida dubliniensis, in vulvovaginal candidiasis. Med Mycol 2014, 52(6):636-640
Pukkila-Worley R, Peleg AY, Tampakakis E, Mylonakis E: Candida albicans hyphal formation and virulence assessed using a Caenorhabditis elegans infection model. Eukaryotic cell 2009, 8(11):1750-1758
Beck-Sague C, Jarvis WR: Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. The Journal of infectious diseases 1993, 167(5):1247-1251
Gibbons JD: Nonparametric statistical inference. New York: McGraw Hill; 1971
Castellan NJ, Siegel S: Nonparametric statistics for the behavioral science, 2nd edn: McGraw-Hill Publishing Co; 1988
Yang SP, Chen YY, Hsu HS, Wang FD, Chen LY, Fung CP: A risk factor analysis of healthcare-associated fungal infections in an intensive care unit: a retrospective cohort study. BMC infectious diseases 2013, 13:10
Chandra RK: Impact of nutritional status and nutrient supplements on immune responses and incidence of infection in older individuals. Ageing research reviews 2004, 3(1):91-104
Ostrosky-Zeichner L, Pappas PG, Shoham S, Reboli A, Barron MA, Sims C, Wood C, Sobel JD: Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. Mycoses 2009, 54(1):46-51
Bastert J, Schaller M, Korting HC, Evans EG: Current and future approaches to antimycotic treatment in the era of resistant fungi and immunocompromised hosts. International journal of antimicrobial agents 2001, 17(2):81-91
Diekema DJ, Pfaller MA: Nosocomial candidemia: an ounce of prevention is better than a pound of cure. Infect Control Hosp Epidemiol 2004, 25(8):624-626
Sobel JD, Rex JH: Invasive candidiasis: turning risk into a practical prevention policy? Clin Infect Dis 2001, 33(2):187-190
Rodriguez-Leguizamon G, Fiori A, Lagrou K, Gaona MA, Ibanez M, Patarroyo MA, Van Dijck P, Gomez-Lopez A: New echinocandin susceptibility patterns for nosocomial Candida albicans in Bogota, Colombia, in ten tertiary care centres: an observational study. BMC infectious diseases 2015, 15:108
Ben-Ami R, Garcia-Effron G, Lewis RE, Gamarra S, Leventakos K, Perlin DS, Kontoyiannis DP: Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. The Journal of infectious diseases 2011, 204(4):626-635
Slater JL, Howard SJ, Sharp A, Goodwin J, Gregson LM, Alastruey-Izquierdo A, Arendrup MC, Warn PA, Perlin DS, Hope WW: Disseminated Candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin. Antimicrobial agents and chemotherapy 2011, 55(7):3075-3083
Romeo O, Criseo G: Candida africana and its closest relatives. Mycoses 2011, 54(6):475-486
Gil-Alonso S, Jauregizar N, Canton E, Eraso E, Quindos G: Comparison of the in vitro activity of echinocandins against Candida albicans, Candida dubliniensis, and Candida africana by time-kill curves. Diagnostic microbiology and infectious disease 2015, 82(1):57-61
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario

Candida albicans es el hongo patógeno que con mayor frecuencia compromete a los pacientes en el ambiente hospitalario, su versatilidad para adaptarse al huésped le ha permitido jugar el rol de comensal colonizador de tracto digestivo, tracto genito

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3760a2a69b104a0bb5212d83f67d914e

Análise proteômica comparativa dos componentes da superfície celular e do secretoma de Aspergillus fumigatus

Autor: Paula Helena Kubitschek Barreira

Publikováno v: Biblioteca Digital de Teses e Dissertações da UERJUniversidade do Estado do Rio de JaneiroUERJ.

Conselho Nacional de Desenvolvimento Científico e Tecnológico
Aspergillus fumigatus é o principal agente etiológico da aspergilose invasiva, infecção fúngica oportunista com altas taxas de mortalidade afetando, principalmente, pacientes c

Externí odkaz: http://www.bdtd.uerj.br/tde_busca/arquivo.php?codArquivo=4707

The immunomodulator PSK induces in vitro cytotoxic activity in tumour cell lines via arrest of cell cycle and induction of apoptosis

Autor: Federico Garrido, Irene Romero, Enrique Berruguilla, Ignacio Algarra, Angel M. Garcia-Lora, Eva Jiménez-Medina, Antonia Collado

Publikováno v: BMC Cancer, Vol 8, Iss 1, p 78 (2008)
BMC Cancer
Digibug. Repositorio Institucional de la Universidad de Granada
instname

Background Protein-bound polysaccharide (PSK) is derived from the CM-101 strain of the fungus Coriolus versicolor and has shown anticancer activity in vitro and in in vivo experimental models and human cancers. Several randomized clinical trials have

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fa115ce8dd2a827ef39b8821894b038
http://www.biomedcentral.com/1471-2407/8/78